Covenant Health’s Cumberland Medical Center was the first in East Tennessee to introduce new robotic technology powered by ...

Caris Life Sciences® , a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) testing ...

A US government study finds racial disparities in care and a complicated relationship between distance to major cancer centers and patients’ treatment and outcomes.

A quality improvement study analyzed the value of advanced telehealth delivery methods during prostate cancer management.

Federal health officials are quietly moving to overhaul the fine print on testosterone replacement therapy, a shift that ...

In the United States, prostate cancer is a leading cause of cancer-related disease and death in men. About half of prostate ...

The study is aimed at advancing personalized cancer treatment by exploring a personalized approach to radioligand therapy.

NeoGenomics, Inc.(NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) ...

GE HealthCare GEHC has announced a new research collaboration with Mayo Clinic to advance personalized cancer treatment ...

The partnership will evaluate whether imaging- and biomarker-informed insights can support a more personalised approach to ...

Tiny silica nanoparticles engineered to seek out prostate cancer caused tumor cells to self-destruct and supercharged the ...

The MI-BET study, which will take place at Mayo Clinic in Rochester, will see if radioligand therapy, an emerging treatment ...